EDIT vs LYB · rev $32.3M vs P/E 21, rev $40.30B
Editas Medicine Inc (EDIT) versus LyondellBasell Industries NV (LYB) — a side-by-side from cached financials, not a winner call.
Editas Medicine Inc (EDIT) is a biotechnology company listed on NASDAQ.
LyondellBasell Industries NV (LYB) is a specialty chemicals company listed on US.
Latest reported EDIT revenue for 2024-12-31 was $32.3M. Net income was -$237.1M. Revenue was down 58.6% from 2023-12-31 to 2024-12-31. EDIT currently screens at market cap $375.2M.
Latest reported LYB revenue for 2024-12-31 was $40.30B. Net income was $1.37B. Revenue was down 2.0% from 2023-12-31 to 2024-12-31. LYB currently screens at market cap $19.93B and trailing P/E 21.5.
EDIT currently screens at market cap $375.2M. LYB currently screens at market cap $19.93B and trailing P/E 21.5.
Not investment advice. Open the EDIT and LYB stock pages for the full models.
Not investment advice.